Novavax, Inc. (Nasdaq:NVAX) announced the publication of an article that reported new safety, immunogenicity and cross-reactivity results from a Phase I/IIa clinical study of the company's H5N1 influenza virus-like particle (VLP) vaccine candidate that was conducted in 2008.

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant vaccines for infectious diseases using its virus-like particle platform technology.

To read more: http://drstockpick.com/?p=21961